Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - solution - 10 mg in 5 ml - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the concurrent use of nortriptyline hydrochloride or other tricyclic antidepressants with a monoamine oxidase (mao) inhibitor is contraindicated. hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. it is advisable to discontinue the mao inhibitor at least 2 weeks before treatment with nortriptyline hydrochloride is to be started. patients hypersensitive to nortriptyline hydrochloride should not be given the drug. cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

implant solutions pty ltd (trading as osteon medical) - 44879 - dental implant suprastructure device, permanent - a prefabricated device that is incorporated into, or creates, the necessary suprastructure mimicking preparations of natural teeth. it is used during dental implant restorative procedures and will provide the permanent intermediate fixture level between the dental implant and the final restoration (e.g., bridge, single tooth, overdenture)

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - nortriptyline hydrochloride, quantity: 11.4 mg (equivalent: nortriptyline, qty 10 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - treatment of major depression

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - nortriptyline hydrochloride, quantity: 28.5 mg (equivalent: nortriptyline, qty 25 mg) - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate - treatment of major depression

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

par pharmaceutical, inc. - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 10 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 25 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - amitriptyline hydrochloride 10 mg - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with a gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infa